Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

DiGeorge Syndrome

  • Author: Erawati V Bawle, MD, FAAP, FACMG; Chief Editor: Harumi Jyonouchi, MD  more...
 
Updated: May 17, 2016
 

Practice Essentials

DiGeorge syndrome (DGS) is one of a group of phenotypically similar disorders—including velocardiofacial syndrome (VCFS, or Shprintzen syndrome) and conotruncal anomaly face (CTAF) syndrome—that share a microdeletion of the region, known as the DGS critical region, on chromosome 22 at band 22q11.2 (see the image below). These overlapping conditions are now termed as a 22q11.2 deletion syndrome (22q11.2DS) and in the rest of the article will be referred to as 22q11.2DS.

Mother and children with 22q11.2 deletion syndrome Mother and children with 22q11.2 deletion syndrome.

Although the prognosis for 22q11.2DS varies widely, depending largely on the nature and degree of involvement of different organs, many adults live long and productive lives.

Signs and symptoms

Patients with 22q11.2 DS usually have characteristic facies. Common features include the following (see the images below)[1] :

  • Retrognathia or micrognathia
  • Long face
  • High and broad nasal bridge
  • Narrow palpebral fissures
  • Small teeth
  • Asymmetrical crying face
  • Downturned mouth
  • Short philtrum
  • Low-set, malformed ears
  • Hypertelorism

Congenital heart defects, either a cleft palate or incompetence of the soft palate, and immune deficiencies are common. Patients may have short stature and occasional instances of growth hormone deficiency. Renal, pulmonary, gastrointestinal (GI), skeletal, and ophthalmologic abnormalities can also occur.

Children and adults with 22q11.2DS have high rates of behavioral, psychiatric, and communication disorders. In children, these include attention-deficit/hyperactivity disorder, anxiety, autism, and affective disorders. Adults have a high rate of psychotic disorders, particularly schizophrenia.

See Clinical Presentation for more detail.

Diagnosis

Genetic studies

  • Chromosomal microarray analysis (CMA) or array comparative genomic hybridization (aCGH)
  • Fluorescent in situ hybridization (FISH)
  • TBX1 gene studies
  • Multiplex ligation-dependent probe amplification (MLPA)

Additional laboratory tests

  • Complete blood cell (CBC) count
  • Serum calcium and parathyroid hormone (PTH) studies

Evaluation of T-cell count and function

  • Flow cytometry
  • Reverse-transcriptase polymerase chain reaction (RT PCR) assay to assess thymic T-cell out for detection of TCR excision circles (TREC)
  • Antibody response studies

Imaging studies

Imaging studies used in the diagnosis of thymic and cardiovascular abnormalities in 22q11.2DS include the following:

  • Radiography
  • Magnetic resonance imaging (MRI)
  • Computed tomography (CT) scanning
  • Echocardiography
  • Angiography and magnetic resonance angiography (MRA)

See Workup for more detail.

Management

Congenital heart defect

If a heart murmur and or other signs of a heart defect are present, consult a cardiologist right away, especially in the neonatal period.

Hypocalcemia

Begin calcium supplementation after proper tests (simultaneous serum calcium and serum PTH levels) are performed. Vitamin D supplementation may become necessary.

Immune reconstitution

Early thymus transplantation (ie, before the onset of infectious complications) may promote successful immune reconstitution for subjects with complete absence of thymus (1% of 22q11.2DS subjects). A potential alternative treatment, adoptive transfer of mature T cells (ATMTC) through bone marrow transplantation has emerged as a successful therapy for 22q11.2DS.

For subjects with thymic hypoplasia, prophylactic antibiosis and antifungals are helpful for the first year of life. Management of autoimmune complications are important for older subjects.

Surgery

Cleft palate can be repaired with surgical modalities.[2]

Glottic web can be managed with surgical reconstruction or tracheotomy.[3]

Early intervention services

Monitor neurodevelopment and speech development, and refer the patient for educational therapies.

See Treatment and Medication for more detail.

Next

Background

22q11.2DS (DiGeorge syndrome, or DGS) has a wide range of clinical features, including the following:

  • Abnormal facies
  • Congenital heart defects
  • Cognitive, behavioral, and psychiatric problems
  • Increased susceptibility to infections due to thymic aplasia or hypoplasia

Some collectively refer to these by the acronym CATCH-22 (cardiac defects, abnormal facies, thymic hypoplasia, cleft palate, and hypocalcemia resulting from 22q11.2 deletion). This designation has not been in use recently. See the image below. (See DDx and Workup.)

Mother and children with 22q11.2 deletion syndrome Mother and children with 22q11.2 deletion syndrome.

22q11.2DS encompasses the following phenotypically similar disorders—including DiGeorge syndrome:

  • Velocardiofacial syndrome (VCFS, or Shprintzen syndrome)
  • Cayler cardiofacial syndrome (asymmetric crying facies)
  • Conotruncal anomaly face (CTAF) syndrome
  • Some cases of autosomal dominant Opitz G/BBB syndrome

These syndromes were described as separate entities based on their prominent features and prior to the discovery that the microdeletion of the DGS critical region, on band chromosome 22 at band 22q11.2 was the underlying cause in most of them.

DiGeorge syndrome was originally described as a developmental field defect in the third and fourth branchial pouches, often presenting in the neonatal period with hypocalcemia and severe immune deficiency. Later, conotruncal heart defects in DiGeorge syndrome were included. Velocardiofacial syndrome, on the other hand, was initially recognized as a syndrome of palatal defects, conotruncal heart defects, and characteristic facial features. (See Pathophysiology and Etiology.)

Immunologic classification of partial versus complete 22q11.2DS

Thymic hypoplasia or aplasia leading to defective T-cell function is one of the main features of 22q11.2DS. Depending on the T-cell proliferative responses to mitogens, the immunologic features of 22q11.2DS can be classified as partial or complete. Patients with partial 22q11.2DS have a below-normal proliferative response to mitogens, and the immune parameters may improve with time. Interleukin (IL)–7 may play a critical role in T-cell homeostasis in patients with partial 22q11.2DS.[4] However, in subjects with thymic hypoplasia, despite compensatory increase of T-cell numbers, TCR repertoire is reported to be decreased than normal controls.

Patients with complete 22q11.2DS are rare and have no T-cell responses to mitogens. These patients usually have very few detectable T cells in peripheral blood (1-2%) and usually require treatment of thymic transplant or hematopoietic stem cell transplantation. (See Treatment and Medication.)

B-cell defects

Although 22q11.2DS is categorized as a T-lymphocyte immunodeficiency, B-lymphocyte defects also occur. A review of 1023 patients with DGS revealed that 6% of patients older than 3 years had hypogammaglobulinemia and that 3% of patients with DGS were receiving immunoglobulin replacement therapy.[5]

Previous
Next

Pathophysiology

The result of the 22q11.2 deletion is a range of embryonic developmental disruptions involving the head, neck, brain, skeleton, and kidneys. Portions of the heart, head and neck, thymus, and parathyroids derive from the third and fourth pharyngeal pouches, and a developmental field defect results from the chromosomal microdeletion. This, in turn, leads to hypocalcemia and variable T-cell deficiency. A combined T- and B-cell deficiency in part results from lack of T-helper cell function as seen in cases of complete 22q11.2DS.

Disease mechanism

The syndrome is caused by a microdeletion of band 22q11.2. The long arm of chromosome 22 (at q11) is prone to a microdeletion because of the presence of nonallelic, flanking, low-copy repeat deoxyribonucleic acid (DNA) sequences labeled A-D. These sequences lead to meiotic nonallelic crossing over between the 2 copies of chromosome 22 during spermatogenesis or oogenesis.

The most common deletion present in 85% of individuals is 3 million base pair (Mb) in size, extends from A to D, and encompasses approximately 40 genes and 4 micro RNAs. Among them is the TBX1 gene, suspected to play a major role in many of the typical features of this syndrome. However, which other genes must be deleted remains unknown, and no genotype-phenotype correlation has been elucidated. The remaining 15% of affected individuals have atypical smaller deletions.

Among other genes mapped in the deleted region that have been implicated in the pathogenesis of 22q11.2DS include HIRA (a transcriptional corepressor of cell cycle–dependent histone gene transcription and mammalian homologue of the yeast Hir1p and Hir2p proteins) and UFD1L (homologue of a highly conserved yeast gene involved in the degradation of ubiquitinated genes).

Disease mechanism of immunodeficiency

The characteristic immunodeficiency in 22q11.2DS is a mild to moderate defect in T-cell lineage caused by thymic hypoplasia in subjects with incomplete DGS. Naïve T-cell production is usually reduced with resultant low TREC (T-cell receptor excision circles) detected by PCR. Only a small fraction of patients present with marked impairment of T-cell function associated with a complete absence of thymus/T-cells, and severe systemic infections, consistent with severe combined immunodeficiency phenotype. Improvement with age in T-cell functions and numbers may be attributed to homeostatic T-cell proliferation secondary to limited T-cell production.

Variable secondary humoral defects, including hypogammaglobulinemia and selective antibody deficiency, may be present.

Disease mechanism of autoimmune diseases

Impaired T-cell production may predispose patients with 22q11.2 deletion to autoimmune diseases. In a cohort of 195 patients with 22q11.2DS, various autoimmune diseases, including juvenile rheumatoid arthritis, idiopathic thrombocytopenic purpura, and autoimmune hemolytic anemia, were each more prevalent than in the age-matched general population.[6] No specific pattern of autoimmune disease appears to be associated with 22q11.2 deletion.

The frequency of autoimmune disorders in patients with partial 22q11.2DS was reviewed by Tison et al[7] in a large cohort of pediatric patients, and in that review, cytopenias and hypothyroidism were reported to be the most common autoimmune conditions. Autoimmunity was found in 10 (8.5%) of 130 patients, a frequency similar to that seen in a previous study in a different institution. Children with high or normal naive CD4 T-cell counts early in childhood had a lower risk of autoimmune disease.

Association with Graves disease has been reported sporadically.[8, 9] Other associated diseases include immune cytopenias,[10] immune thrombocytopenic purpura,[11] juvenile rheumatoid arthritis–like polyarthritis,[12] autoimmune uveitis,[13] and severe eczema.[14]

DiGeorge syndrome and velocardiofacial syndrome (VCFS) have also been found to be significantly associated with asthma but not with allergic rhinitis.[15]

Disease mechanisms of neuropsychiatric disorders

The 22q11.2 microdeletion is the strong known genetic risk factor for schizophrenia and has been implicated with microRNA (miRNA)-mediated dysregulation. Primary candidate genes for this condition are DiGeorge syndrome critical region gene 8 (DGCR8), which encodes a component of the microprocessor complex essential for miRNA biogenesis and miR-185.[16] miR-185 is reported to be down-regulated in brains of schizophrenia patients and also is reported to be down-regulated in patients with 22q11.2 DiGeorge syndrome.[17]

Mode of inheritance

The occurrence of 22q11.2DS is sporadic in more than 90% of cases, being the result of de novo (noninherited) deletions. About 10% have inherited the deletion from a parent as an autosomal dominant condition. Sibling involvement has been observed only if a chromosome 22 deletion has been found in a parent. The hereditary cases show no predilection in inheritance from the mother or father, and an affected person has a 50% chance of transmitting the condition to his or her child. Wide intrafamily and interfamily variability in clinical manifestations is seen.

Previous
Next

Epidemiology

Estimates of the incidence of 22q11.2DS range from 1 per 2000 to 1 per 4000 persons in the general population of the United States, as well as internationally. It is a frequent cause of cleft palate and congenital heart defects.

Although 22q11.2DS is a congenital condition, the age at diagnosis largely depends on its severity and on the types of birth defects it causes. Thus, patients with more serious cardiac defects or hypocalcemia are diagnosed in the neonatal period. Recurrent infections usually present in patients older than 3-6 months.

Some individuals without hypocalcemia who have normal immune function, mild cardiac defects, and minimal facial anomalies may remain undiagnosed until late childhood. Late diagnosis into adulthood continues to be reported, especially in persons with isolated mild symptoms. Prenatal diagnosis in fetuses with a congenital heart anomaly has been made frequently and should be offered to a pregnant woman at risk of carrying a fetus with this syndrome.

Previous
Next

Prognosis

The prognosis for 22q11.2DS varies widely, depending largely on the nature and degree of involvement of different organs, and many adults live long and productive lives.

The most common cause of mortality in 22q11.2DS is a congenital heart defect and the second most common is severe immune deficiency. Mortality is higher in infancy because of the severity of these 2 conditions. Infants with thymus aplasia present with severe immunodeficiency and typically die of sepsis, which usually results from bacterial or fungal infections.

In a large European collaborative study, 558 patients with 22q11.2DS were evaluated using a questionnaire.[18] Eight percent of the patients died, with more than half of the deaths occurring within the first month of life and the majority happening within 6 months of birth. Of the patients who survived, 62% had only mild learning problems or were developmentally normal. All but one of the deaths was attributable to congenital heart disease.

Previous
Next

Patient Education

Genetic counseling is essential to educate parents regarding the recurrence risk of 22q11.2DS. In addition, the families of patients with clinically significant immunodeficiency should be educated regarding the potential complications from exposure to live-attenuated vaccines that include rotavirus vaccine, MMR vaccine, and chicken pox vaccine.

Patients' families often feel alone after the syndrome is diagnosed. Because of its rarity, most parents have neither heard of this disorder nor do they know anyone who has it to whom they can turn to for support. Support groups and other resources are of invaluable help in this regard. Many written educational materials are available through various organizations, including those listed below.

International 22q11.2 Deletion Syndrome Foundation, Inc

PO Box 2269

Cinnaminson, NJ 08077 USA

Telephone: 877-739-1849; email: info@22q.org

www.22q.org

Max Appeal

15 Meriden Ave

Stourbridge, West Midlands; DY8 4QN United Kingdom

Telephone: 0800-389-1049; email: info@maxappeal.org.uk

www.maxappeal.org.uk

National Library of Medicine Genetics Home Reference: 22q11.2 deletion syndrome

National Center for Biotechnology Information (NCBI) Genes and Disease: DiGeorge syndrome

Velo-Cardio-Facial Syndrome Education Foundation, Inc

PO Box 874

Milltown, NJ 08850, USA

Telephone 1-866-823 7335); email: info@vcfsef.org

www.vcfsef.org

Chromosome 22 Central

338 Spruce Street North

Timmins Ontario P4N 6N5 Canada

Telephone: 705-268-3099; email: steph.stpierre@c22c.org

www.c22c.org

Previous
 
 
Contributor Information and Disclosures
Author

Erawati V Bawle, MD, FAAP, FACMG Retired Professor, Department of Pediatrics, Wayne State University School of Medicine

Erawati V Bawle, MD, FAAP, FACMG is a member of the following medical societies: American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD Faculty, Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, Saint Peter's University Hospital

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Pediatric Research, Society for Mucosal Immunology

Disclosure: Nothing to disclose.

Acknowledgements

David F Butler, MD Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Mark A Crowe, MD Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine

Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society

Disclosure: Nothing to disclose.

Daniel AC Frattarelli, MD, FAAP Senior Staff, Departments of Pediatrics and Emergency Medicine, Henry Ford Hospital

Daniel AC Frattarelli, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Clinical Pharmacology, and American Society for Clinical Pharmacology and Therapeutics

Disclosure: Nothing to disclose.

Sridhar Guduri, MD Consulting Staff, Allergy and Asthma Clinics of Ohio

Sridhar Guduri, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology and American College of Allergy, Asthma and Immunology

Disclosure: Nothing to disclose.

Iftikhar Hussain, MD Director of Allergy, Asthma, and Immunology Center, PC

Iftikhar Hussain, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, American College of Physicians, American Thoracic Society, and Association of Clinical Research Professionals

Disclosure: Nothing to disclose.

Suguru Imaeda, MD Chief of Dermatology, Yale University Health Services; Chief of Dermatology, West Haven Veterans Affairs Medical Center; Assistant Professor, Department of Dermatology, Yale University School of Medicine

Suguru Imaeda, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Connecticut State Medical Society, Sigma Xi, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Elsevier Royalty Other

Michael A Kaliner, MD Clinical Professor of Medicine, George Washington University School of Medicine; Chief, Section of Allergy and Immunology, Washington Hospital Center; Medical Director, Institute for Asthma and Allergy

Michael A Kaliner, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American Society for Clinical Investigation, American Thoracic Society, and Association of American Physicians

Disclosure: Alcon Consulting fee Consulting; Teva Consulting fee Consulting; Meda Honoraria Speaking and teaching; Ista Consulting fee Consulting; sunovian Consulting fee Consulting; dey Honoraria Review panel membership

Charles H Kirkpatrick, MD

Charles H Kirkpatrick is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Physicians, American Federation for Clinical Research, American Society for Clinical Investigation, and Clinical Immunology Society

Disclosure: Dyax Consulting fee Consulting

C Lucy Park, MD Head, Division of Allergy, Immunology, and Pulmonology, Associate Professor, Department of Pediatrics, University of Illinois at Chicago College of Medicine

C Lucy Park, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Medical Association, Chicago Medical Society, Clinical Immunology Society, and Illinois State Medical Society

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Patrick Htain Win MD, President/Director, Allergy, Asthma and Immunology Center, SC; Director, The Clinical Research Center of Southern Illinois, LLC

Patrick Htain Win is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, and Joint Council of Allergy, Asthma and Immunology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Butts SC. The facial phenotype of the velo-cardio-facial syndrome. Int J Pediatr Otorhinolaryngol. 2009 Mar. 73(3):343-50. [Medline].

  2. Nugent N, McGillivary A, Earley MJ. 22q11 chromosome abnormalities and the cleft service. J Plast Reconstr Aesthet Surg. 2010 Apr. 63(4):598-602. [Medline].

  3. Cheng AT, Beckenham EJ. Congenital anterior glottic webs with subglottic stenosis: surgery using perichondrial keels. Int J Pediatr Otorhinolaryngol. 2009 Jul. 73(7):945-9. [Medline].

  4. Tantibhaedhyangkul U, Davis CM, Noroski LM, Hanson IC, Shearer WT, Chinen J. Role of IL-7 in the regulation of T-cell homeostasis in partial DiGeorge syndrome. J Allergy Clin Immunol. 2009 Apr. 123(4):960-2.e2. [Medline].

  5. Patel K, Akhter J, Kobrynski L, Benjamin Gathmann MA, Davis O, Sullivan KE. Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge Syndrome. J Pediatr. 2012 Nov. 161(5):950-3. [Medline].

  6. Jawad AF, McDonald-Mcginn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. 2001 Nov. 139(5):715-23. [Medline].

  7. Tison BE, Nicholas SK, Abramson SL, Hanson IC, Paul ME, Seeborg FO, et al. Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J Allergy Clin Immunol. 2011 Nov. 128(5):1115-7.e1-3. [Medline].

  8. Kawamura T, Nimura I, Hanafusa M, Fujikawa R, Okubo M, Egusa G, et al. DiGeorge syndrome with Graves' disease: A case report. Endocr J. 2000 Feb. 47(1):91-5. [Medline].

  9. Ham Pong AJ, Cavallo A, Holman GH, Goldman AS. DiGeorge syndrome: long-term survival complicated by Graves disease. J Pediatr. 1985 Apr. 106(4):619-20. [Medline].

  10. DePiero AD, Lourie EM, Berman BW, Robin NH, Zinn AB, Hostoffer RW. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr. 1997 Sep. 131(3):484-6. [Medline].

  11. Lévy A, Michel G, Lemerrer M, Philip N. Idiopathic thrombocytopenic purpura in two mothers of children with DiGeorge sequence: a new component manifestation of deletion 22q11?. Am J Med Genet. 1997 Apr 14. 69(4):356-9. [Medline].

  12. Sullivan KE, McDonald-McGinn DM, Driscoll DA, Zmijewski CM, Ellabban AS, Reed L, et al. Juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome (DiGeorge anomalad/velocardiofacial syndrome/conotruncal anomaly face syndrome). Arthritis Rheum. 1997 Mar. 40(3):430-6. [Medline].

  13. Gottlieb C, Li Z, Uzel G, Nussenblatt RB, Sen HN. Uveitis in DiGeorge syndrome: a case of autoimmune ocular inflammation in a patient with deletion 22q11.2. Ophthalmic Genet. 2010 Mar. 31(1):24-9. [Medline]. [Full Text].

  14. Archer E, Chuang TY, Hong R. Severe eczema in a patient with DiGeorge's syndrome. Cutis. 1990 Jun. 45(6):455-9. [Medline].

  15. Staple L, Andrews T, McDonald-McGinn D, Zackai E, Sullivan KE. Allergies in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) and patients with chronic granulomatous disease. Pediatr Allergy Immunol. 2005 May. 16(3):226-30. [Medline].

  16. Forstner AJ, Degenhardt F, Schratt G, Nothen MM. MicroRNAs as the cause of schizophrenia in 22q11.2 deletion carriers, and possible implications for idiopathic disease: a mini-review. Front Mol Neurosci. 12/2013. 6:47.

  17. de la Morena MT, Elitson JL, Dozmorov IM, Belkaya S, Hoover AR, Anguiano E, et al. Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome. Clin Immunol. 04/2013. 147:11-22.

  18. Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet. 1997 Oct. 34(10):798-804. [Medline]. [Full Text].

  19. McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 2011 Jan. 90(1):1-18. [Medline].

  20. Marcinkowski M, Bauer K, Stoltenburg-Didinger G, Vogel M, Versmold H. Fatal aspergillosis with brain abscesses in a neonate with DiGeorge syndrome. Pediatr Infect Dis J. 2000 Dec. 19(12):1214-6. [Medline].

  21. Sánchez-Velasco P, Ocejo-Vinyals JG, Flores R, Gómez-Román JJ, Lozano MJ, Leyva-Cobián F. Simultaneous multiorgan presence of human herpesvirus 8 and restricted lymphotropism of Epstein-Barr virus DNA sequences in a human immunodeficiency virus-negative immunodeficient infant. J Infect Dis. 2001 Jan 15. 183(2):338-342. [Medline].

  22. Minakawa S, Nakano H, Takeda H, Mizukami H, Yagihashi S, Satou T, et al. Chromosome 22q11.2 deletion syndrome associated with severe eczema. Clin Exp Dermatol. 2009 Apr. 34(3):410-1. [Medline].

  23. Furniss F, Biswas AB, Gumber R, Singh N. Cognitive phenotype of velocardiofacial syndrome: a review. Res Dev Disabil. 2011 Nov-Dec. 32(6):2206-13. [Medline].

  24. Hacihamdioglu B, Berberoglu M, Siklar Z, Dogu F, Bilir P, Savas Erdeve S, et al. Case report: two patients with partial DiGeorge syndrome presenting with attention disorder and learning difficulties. J Clin Res Pediatr Endocrinol. 2011. 3(2):95-7. [Medline]. [Full Text].

  25. Antshel KM, Shprintzen R, Fremont W, Higgins AM, Faraone SV, Kates WR. Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry. 2010 Apr. 49(4):333-44. [Medline]. [Full Text].

  26. Sieberer M, Runte I, Wilkening A, Pabst B, Ziegenbein M, Haltenhof H. [Spectrum of neuropsychiatric features associated with velocardiofacial syndrome (Deletion 22q11.2)]. Fortschr Neurol Psychiatr. 2006 May. 74(5):263-74. [Medline].

  27. Klaassen P, Duijff S, Swanenburg de Veye H, Vorstman J, Beemer F, Sinnema G. Behavior in preschool children with the 22q11.2 deletion syndrome. Am J Med Genet A. 2013 Jan. 161A(1):94-101. [Medline].

  28. Choi JH, Shin YL, Kim GH, Seo EJ, Kim Y, Park IS, et al. Endocrine manifestations of chromosome 22q11.2 microdeletion syndrome. Horm Res. 2005. 63(6):294-9. [Medline].

  29. Johnston PC, Donnelly DE, Morrison PJ, Hunter SJ. DiGeorge syndrome presenting as late onset hypocalcaemia in adulthood. Ulster Med J. 2008 Sep. 77(3):201-2. [Medline]. [Full Text].

  30. Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009. 44(1-3):61-70. [Medline].

  31. McDonald-McGinn DM, Reilly A, Wallgren-Pettersson C, et al. Malignancy in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Am J Med Genet A. 2006 Apr 15. 140(8):906-9. [Medline].

  32. Baylis AL, Watson PJ, Moller KT. Structural and functional causes of hypernasality in velocardiofacial syndrome. A pilot study. Folia Phoniatr Logop. 2009. 61(2):93-6. [Medline].

  33. da Silva Dalben G, Richieri-Costa A, de Assis Taveira LA. Tooth abnormalities and soft tissue changes in patients with velocardiofacial syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Aug. 106(2):e46-51. [Medline].

  34. Forbes BJ, Binenbaum G, Edmond JC, DeLarato N, McDonald-McGinn DM, Zackai EH. Ocular findings in the chromosome 22q11.2 deletion syndrome. J AAPOS. 2007 Apr. 11(2):179-82. [Medline].

  35. Gilmour DF, Downey LM, Sheridan E, Long V, Bradbury J, Inglehearn CF, et al. Familial exudative vitreoretinopathy and DiGeorge syndrome: a new locus for familial exudative vitreoretinopathy on chromosome 22q11.2?. Ophthalmology. 2009 Aug. 116(8):1522-4. [Medline].

  36. Binenbaum G, McDonald-McGinn DM, Zackai EH, Walker BM, Coleman K, Mach AM, et al. Sclerocornea associated with the chromosome 22q11.2 deletion syndrome. Am J Med Genet A. 2008 Apr 1. 146(7):904-9. [Medline]. [Full Text].

  37. Kokitsu-Nakata NM, Guion-Almeida ML, Richieri-Costa A. 22q11 deletion syndrome and limb anomalies: report on two Brazilian patients. Cleft Palate Craniofac J. 2008 Sep. 45(5):561-6. [Medline].

  38. Bittel DC, Yu S, Newkirk H, Kibiryeva N, Holt A 3rd, Butler MG, et al. Refining the 22q11.2 deletion breakpoints in DiGeorge syndrome by aCGH. Cytogenet Genome Res. 2009. 124(2):113-20. [Medline]. [Full Text].

  39. Cho EH, Park BY, Cho JH, Kang YS. Comparing two diagnostic laboratory tests for several microdeletions causing mental retardation syndromes: multiplex ligation-dependent amplification vs fluorescent in situ hybridization. Korean J Lab Med. 2009 Feb. 29(1):71-6. [Medline].

  40. Sørensen KM, Agergaard P, Olesen C, Andersen PS, Larsen LA, Ostergaard JR, et al. Detecting 22q11.2 deletions by use of multiplex ligation-dependent probe amplification on DNA from neonatal dried blood spot samples. J Mol Diagn. 2010 Mar. 12(2):147-51. [Medline]. [Full Text].

  41. Naqvi N, Davidson SJ, Wong D, Cullinan P, Roughton M, Doughty VL, et al. Predicting 22q11.2 deletion syndrome: a novel method using the routine full blood count. Int J Cardiol. 2011 Jul 1. 150(1):50-3. [Medline].

  42. Knutsen AP, Baker MW, Markert ML. Interpreting low T-cell receptor excision circles in newborns with DiGeorge anomaly: importance of assessing naive T-cell markers. J Allergy Clin Immunol. 2011 Dec. 128(6):1375-6. [Medline].

  43. de Almeida JR, James AL, Papsin BC, Weksburg R, Clark H, Blaser S. Thyroid gland and carotid artery anomalies in 22q11.2 deletion syndromes. Laryngoscope. 2009 Aug. 119(8):1495-500. [Medline].

  44. Driscoll DA. Prenatal diagnosis of the 22q11.2 deletion syndrome. Genet Med. 2001 Jan-Feb. 3(1):14-8. [Medline].

  45. Shefi S, Raviv G, Rienstein S, Barkai G, Aviram-Goldring A, Levron J. Fish based preimplantation genetic diagnosis to prevent DiGeorge syndrome. J Assist Reprod Genet. 2009 Jul. 26(7):411-3. [Medline]. [Full Text].

  46. McDonald-McGinn DM, Zackai EH. Genetic counseling for the 22q11.2 deletion. Dev Disabil Res Rev. 2008. 14(1):69-74. [Medline].

  47. Fernández L, Lapunzina P, Arjona D, López Pajares I, García-Guereta L, Elorza D, et al. Comparative study of three diagnostic approaches (FISH, STRs and MLPA) in 30 patients with 22q11.2 deletion syndrome. Clin Genet. 2005 Oct. 68(4):373-8. [Medline].

  48. Choolani M, Ho SS, Razvi K, Ponnusamy S, Baig S, Fisk NM, et al. FastFISH: technique for ultrarapid fluorescence in situ hybridization on uncultured amniocytes yielding results within 2 h of amniocentesis. Mol Hum Reprod. 2007 Jun. 13(6):355-9. [Medline].

  49. Funke BH, Brown AC, Ramoni MF, Regan ME, Baglieri C, Finn CT, et al. A novel, single nucleotide polymorphism-based assay to detect 22q11 deletions. Genet Test. 2007 Spring. 11(1):91-100. [Medline].

  50. Selim MA, Markert ML, Burchette JL, Herman CM, Turner JW. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol. 2008 Apr. 35(4):380-5. [Medline].

  51. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005 May. 94(5 Suppl 1):S1-63. [Medline].

  52. [Guideline] Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004 Feb. 124(4):433-53. [Medline].

  53. Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, Habel A, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr. 2011 Aug. 159(2):332-9.e1. [Medline]. [Full Text].

  54. Waters V, Peterson KS, LaRussa P. Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child. 2007 Jun. 92(6):519-20. [Medline]. [Full Text].

  55. Azzari C, Gambineri E, Resti M, Moriondo M, Betti L, Saldias LR, et al. Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome). Vaccine. 2005 Feb 25. 23(14):1668-71. [Medline].

  56. Moylett EH, Wasan AN, Noroski LM, Shearer WT. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol. 2004 Jul. 112(1):106-12. [Medline].

  57. Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics. 2003 Oct. 112(4):e325. [Medline].

  58. Matarazzo P, Tuli G, Fiore L, Mussa A, Feyles F, Peiretti V, et al. Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism. J Pediatr Endocrinol Metab. 2013 Aug 14. 1-7. [Medline].

  59. Goldsobel AB, Haas A, Stiehm ER. Bone marrow transplantation in DiGeorge syndrome. J Pediatr. 1987 Jul. 111(1):40-4. [Medline].

  60. Hong R. Thymus transplants: a look to the future. Birth Defects Orig Artic Ser. 1975. 11(1):357-60. [Medline].

  61. Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15. 109(10):4539-47. [Medline]. [Full Text].

  62. Ciupe SM, Devlin BH, Markert ML, Kepler TB. The dynamics of T-cell receptor repertoire diversity following thymus transplantation for DiGeorge anomaly. PLoS Comput Biol. 2009 Jun. 5(6):e1000396. [Medline]. [Full Text].

  63. Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug. 8(8):1729-36. [Medline]. [Full Text].

  64. Markert ML, Boeck A, Hale LP, Kloster AL, McLaughlin TM, Batchvarova MN, et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med. 1999 Oct 14. 341(16):1180-9. [Medline].

  65. McGhee SA, Lloret MG, Stiehm ER. Immunologic reconstitution in 22q deletion (DiGeorge) syndrome. Immunol Res. 2009. 45(1):37-45. [Medline].

  66. Rouillon I, Leboulanger N, Roger G, Maulet M, Marlin S, Loundon N, et al. Velopharyngoplasty for noncleft velopharyngeal insufficiency: results in relation to 22q11 microdeletion. Arch Otolaryngol Head Neck Surg. 2009 Jul. 135(7):652-6. [Medline].

  67. Widdershoven JC, Stubenitsky BM, Breugem CC, MinkvanderMolen AB. Outcome of velopharyngoplasty in patients with velocardiofacial syndrome. Arch Otolaryngol Head Neck Surg. 2008 Nov. 134(11):1159-64. [Medline].

  68. Driscoll DA, Spinner NB, Budarf ML, McDonald-McGinn DM, Zackai EH, Goldberg RB, et al. Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome. Am J Med Genet. 1992 Sep 15. 44(2):261-8. [Medline].

  69. Jalbrzikowski M, Lazaro MT, Gao F, Huang A, Chow C, Geschwind DH, et al. Transcriptome Profiling of Peripheral Blood in 22q11.2 Deletion Syndrome Reveals Functional Pathways Related to Psychosis and Autism Spectrum Disorder. PLoS One. 2015. 10 (7):e0132542. [Medline].

  70. van der Spek J, Groenwold RH, van der Burg M, van Montfrans JM. TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic Review. J Clin Immunol. 2015 May. 35 (4):416-30. [Medline].

 
Previous
Next
 
Mother and children with 22q11.2 deletion syndrome.
An African American girl with 22q11.2 deletion syndrome.
The same child as in the previous image, showing an asymmetrical crying face.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.